Development and Validation of RP-HPLC Method for Quantitative Estimation of Vinpocetine in Pure and Pharmaceutical Dosage Forms

Table 3

Accuracy studies of vinpocetine in standard and drug-matrix solutions.

	Amount added (μgmL^−1)	Peak area	Amount recovered (μgmL^−1)	% Recovery	Recovery (Mean ±  %RSD)
Standard solution	160	2758830	160.12	100.08
	160	2757741	160.06	100.04	100.05 ± 0.023
	160	2757692	160.05	100.04
	180	3108421	180.41	100.23
	180	3108988	180.44	100.25	100.24 ± 0.012
	180	3109134	180.45	100.25
	200	3463527	201.02	100.51
	200	3463889	201.04	100.52	100.52 ± 0.009
	200	3464117	201.05	100.53
	220	3811741	221.23	100.56
	220	3812077	221.25	100.57	100.56 ± 0.007
	220	3811562	221.22	100.56
	240	4168397	241.93	100.80
	240	4167556	241.88	100.78	100.79 ± 0.012
	240	4167502	241.88	100.78
Drug-matrix solution	160	2773303	160.96	100.60
	160	2772297	160.90	100.56	100.57 ± 0.024
	160	2772063	160.89	100.56
	180	3119142	181.03	100.60
	180	3121001	181.14	100.66	100.63 ± 0.030
	180	3119725	181.06	100.62
	200	3477174	201.81	100.90
	200	3477005	201.80	100.90	100.91 ± 0.015
	200	3477987	201.86	100.92
	220	3831775	222.39	101.10
	220	3831000	222.35	101.08	101.08 ± 0.025
	220	3829872	222.28	101.05
	240	4185580	242.92	101.20
	240	4186378	242.97	101.22	101.21 ± 0.011
	240	4185596	242.92	101.20